How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/polyarticular-juvenile-idiopathic-arthritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Polyarticular Juvenile Idiopathic Arthritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Polyarticular Juvenile Idiopathic Arthritis (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Polyarticular Juvenile Idiopathic Arthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xeljanz	Tofacitinib Citrate	Pfizer	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Xeljanz	tofacitinib	Pfizer	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Simponi	GOLIMUMAB	Centocor Ortho Biotech Inc	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
tocilizumab or sarilumab	tocilizumab-or-sarilumab	Pfizer	monoclonal antibody	interleukin-6 receptor
Simponi	Simponi	Alvotech Swiss AG		Tumor necrosis factor
In open-label phase: treatment with tofacitinib	in-open-label-phase-treatment-with-tofacitinib	Pfizer	Janus kinase inhibitor	Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2)
Tasocitinib	Tasocitinib	Pfizer		Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 5 drugs in Polyarticular Juvenile Idiopathic Arthritis
· 1 drug in Polyarticular Juvenile Idiopathic Arthritis
Alvotech Swiss AG · 1 drug in Polyarticular Juvenile Idiopathic Arthritis
Centocor Ortho Biotech Inc · 1 drug in Polyarticular Juvenile Idiopathic Arthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Polyarticular Juvenile Idiopathic Arthritis:

Cite this brief

Drug Landscape (2026). Polyarticular Juvenile Idiopathic Arthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/polyarticular-juvenile-idiopathic-arthritis. Accessed 2026-06-10.

Polyarticular Juvenile Idiopathic Arthritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing